{"id":"bimatoprost-cutaneous-solution-0-03","safety":{"commonSideEffects":[{"rate":"15%","effect":"Conjunctival hyperemia"},{"rate":"10%","effect":"Eye irritation"},{"rate":"5%","effect":"Blurred vision"}]},"_chembl":{"chemblId":"CHEMBL1200963","moleculeType":"Small molecule","molecularWeight":"415.57"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"Bimatoprost is a prostaglandin analog that mimics the natural ligand of the FP receptor, enhancing the outflow of aqueous humor through the uveoscleral pathway, which is a key mechanism in reducing intraocular pressure in conditions such as glaucoma.","oneSentence":"Bimatoprost activates the prostaglandin F2 alpha receptor (FP receptor), leading to increased uveoscleral outflow of aqueous humor and reduced intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:23:54.269Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT03419715","phase":"PHASE2","title":"Topical Bimatoprost in the Treatment of Migraine","status":"UNKNOWN","sponsor":"Manistee Partners","startDate":"2018-01-05","conditions":"Migraine Disorders, Headache Disorders","enrollment":70},{"nctId":"NCT02176356","phase":"PHASE4","title":"Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-06-30","conditions":"Facial Rhytides, Crow's Feet Lines, Glabellar Lines","enrollment":116},{"nctId":"NCT02505776","phase":"","title":"Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-12-08","conditions":"Eyelash Hypotrichosis","enrollment":1699}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GLASH VISTA™","Latisse®"],"phase":"phase_2","status":"active","brandName":"Bimatoprost cutaneous solution 0.03%","genericName":"Bimatoprost cutaneous solution 0.03%","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bimatoprost activates the prostaglandin F2 alpha receptor (FP receptor), leading to increased uveoscleral outflow of aqueous humor and reduced intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}